Romiplostim for Thrombocytopenia Following Allogeneic Stem Cell Transplantation: A Case Series
We report on the outcomes of five patients at our institution who received romiplostim for either primary engraftment failure or secondary failure of platelet recovery following stem cell transplantation. In total, four out of the five patients demonstrated a response to romiplostim, which was defined as seven consecutive days of platelet count>50 × 109/L with transfusion independence, with two ongoing responses (>365 days each) at the conclusion of the study period. Responses to romiplostim were sustained in the absence of significant bone marrow disease, which was found to contribute to recurrent thrombocytop...
Source: Hematology Oncology and Stem Cell Therapy - July 18, 2018 Category: Cancer & Oncology Source Type: research

Role of Red Blood Cells “Annexin V” and Platelets “P-Selectin” in Patients with Thalassemia
ConclusionThe mean expression of platelets P-selectin in patients with thalassemia major and thalassemia intermedia was significantly higher than that in controls and patients with thalassemia minor. However, its expression was significantly higher in patients with thalassemia intermedia than in those with thalassemia major. Annexin V also showed a positive correlation with P-selectin, and both markers positively correlated with regularity of blood transfusion. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 18, 2018 Category: Cancer & Oncology Source Type: research

A novel TNFRSF1A gene mutation in a patient with tumor necrosis factor receptor-associated periodic syndrome
Publication date: Available online 19 October 2016Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Alireza Khabazi, Mahafarin Maralani, Sasan Andalib, Ebrahim SakhiniaAbstractTumor necrosis factor receptor-associated periodic syndrome (TRAPS) is a periodic fever syndrome inherited in an autosomal dominant fashion. It stems from mutations in the TNFRSF1A (accession number: NM_001065) gene expressing the receptor for tumor necrosis factor α. A patient with TRAPS may present with prolonged episodes of fever attacks, abdominal pain, severe myalgia, and painful erythema on the trunk or extremities. Here, we rep...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Synovial sarcoma of the hard palate: The third case in the medical literature
Publication date: Available online 1 February 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Aseel Doubi, Motaz Doubi, Nabil Alzaher, Asma TulbahAbstractSynovial sarcoma is a high-grade soft tissue sarcoma that rarely arises in the head and neck region. It affects the parapharyngeal space and the hypopharynx most commonly and it has different presentations based on the affected site. In extremely rare occasions, it involves the hard palate such as in our case where a 24-year-old female patient presented with a mass lesion involving the left hard palate, which was identified clinically and by imaging studie...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

A case of T-cell lymphoproliferative disorder associated with hypereosinophilia with excellent response to mycophenolate mofetil
We report a case of T-cell lymphoproliferation associated with hypereosinophilia, which has been successfully treated with mycophenolate mofetil, with resolution of skin lesions and normalization of eosinophil count and immunoglobulin E level. We believe this is a clinically relevant case since this is a rare disease with little known knowledge on its best treatment modality. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Diagnosis of variant RARA translocation using standard dual-color dual-fusion PML/RARA FISH probes: An illustrative report
Publication date: Available online 1 February 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Manish Kumar Singh, Mayur Parihar, Neeraj Arora, Deepak Kumar Mishra, Saurabh Jayant Bhave, Mammen ChandyAbstractAcute promyelocytic leukemia (APML) with variant RARa translocations comprises 1–2% of APML cases. However, the diagnosis of these cases is challenging as the routine practice includes fluorescence in situ hybridization (FISH) reverse transcription polymerase chain reaction targeting the PML and RARA genes to detect PML/RARA fusions. Here, we report a case highlighting the importance of atypical FI...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Acute myeloid leukemia in a patient with thrombocytopenia with absent radii: A case report and review of the literature
We report a case of myelodysplastic syndrome progressing to AML with calreticulin driver mutation in an adult male with TAR syndrome who was successfully treated with hematopoietic allogeneic stem cell transplantation. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Waldenström’s macroglobulinemia masquerading as ovarian cancer with peritoneal carcinomatosis, ascites, and elevated CA-125
Publication date: Available online 31 March 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Patrick Eulitt, Denise Fabian, Crystal Kelly, Jessica Hemminger, Basem M. WilliamAbstractWaldenström’s macroglobulinemia is a rare hematology malignancy which often presents with “B symptoms,” anemia, and thrombocytopenia. A 46-year-old woman presented with 2 months of abdominal distension accompanied by an unintentional 20-lb weight loss. Her abdominal CT scan demonstrated diffuse carcinomatosis with bilateral ovarian lesions and screening labs revealed a markedly elevated CA-125, suggesting a...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Myasthenia gravis after allogeneic bone marrow transplantation: A case report and literature review
Publication date: Available online 18 May 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Yutaka Tsutsumi, Takashi Kamiishi, Ryo Kikuchi, Shinichi Ito, Satomi Matsuoka, Takanori TeshimaAbstractA 52-year-old man with acute myeloid leukemia underwent allogeneic hematopoietic stem cell transplantation and developed extensive chronic graft-versus-host disease and myasthenia gravis (MG), which became involved with oculobulbar and proximal upper and lower limb weakness in 677 days. In the literature, we identified 24 cases where MG developed after allo-SCT. Graft-versus-host disease development and male reci...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report
We describe a case of secondary HLH that did not respond favorably to conventional treatments. Serum inflammatory markers continued to rise significantly with clinical deterioration and worsening pancytopenia. The severe thrombocytopenia and neutropenia were deemed to have contributed to a spontaneous subdural hematoma and candidemia, respectively. Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, was then utilized as a novel salvage therapy based on available in vivo murine data at the time. Following initiation, there was improvement seen in several disease markers, including serum ferritin, lactate dehydrogenase, fibrino...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia—A case report
Publication date: Available online 16 August 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Prajwal Boddu, Ellen Schlette, Beenu Thakral, Guillin Tang, Naveen Pemmaraju, Tapan Kadia, Alessandra Ferrajoli, Farhad Ravandi, William Wierda, Nitin JainAbstractChronic lymphocytic leukemia (CLL) is known to be associated rarely with myeloid malignancies such as acute myelogenous leukemia. In this article, we report an extremely rare occurrence of acute promyelocytic leukemia in a patient with CLL. A 71-year-old man first presented to our clinic with a diagnosis of CLL and worsening motor neuropathy symptoms. It w...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Thrombo-hemorrhagic liability in children with congenital heart diseases
ConclusionPatients with CHD—both cyanotic and acyanotic—have variable degrees of increased liability for both thrombosis and hemorrhage that represents some sort of adaptation to preserve hemostasis and to protect these patients against the clinical presentation of both thrombosis and bleeding. This is to say that CHD patients have their own point of balance between thrombogenicity and bleeding liability. Wide-scale studies are needed to detect the normal levels of different thrombohemorrhagic parameters of these patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Hereditary persistence of hemoglobin F is protective against red cell sickling. A case report and brief review
We describe a case of SCD, in which a patient with high HbF level presented at a very late age (27 years old). We presume the patient’s inherently elevated HbF levels were able to compensate for the hypoxic episodes associated with SCD. The onset of symptoms was delayed as a result of elevated HbF levels. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Double CD38−/CD138− negative multiple myeloma
We present an unusual case of CD138− negative multiple myeloma which had become double CD138−/CD38− negative after treatment with daratumumab by which we would like to illustrate potential pitfalls of both strategies. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Aging and stem cell therapy: AMPK as an applicable pharmacological target for rejuvenation of aged stem cells and achieving higher efficacy in stem cell therapy
Publication date: Available online 19 October 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Mohammadhossein Khorraminejad-Shirazi, Mohammad Farahmandnia, Bahareh Kardeh, Alireza Estedlal, Sina Kardeh, Ahmad MonabatiAbstractIn recent years, tissue regeneration has become a promising field for developing stem cell-based transplantation therapies for human patients. Adult stem cells are affected by the same aging mechanisms that involve somatic cells. One of the mechanisms involved in cellular aging is hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1) and disruption of 5′ adenosine ...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Co-existence of myeloid neoplasm and monoclonal gammopathy; case series and review of literature
Publication date: Available online 6 December 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Navkirti Mittal, Ruchi Gupta, Khaliqur Rahman, Tanvi Gupta, Soniya Nityanand (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience
Publication date: Available online 19 December 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Ghulam Rehman Mohyuddin, Ashley Elizabeth Clark, John Roller, Leyla Shune, Tara Lin, Neil Dunavin, Ajoy Dias, Siddhartha Ganguly, Sunil Abhyankar, Joseph McGuirk, Anurag SinghAbstractSurveillance scans after autologous stem cell transplant (auto-HCT) for patients with relapsed/refractory (RR) diffuse large B Cell lymphoma (DLBCL) have no proven survival benefit. We studied survival differences among patients with RR DLBCL post auto-HCT whose recurrences were detected clinically versus with routine surveillance ima...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation
We report a patient with thymoma complicated by pure red cell aplasia (PRCA) and AAMT who progressed to develop aplastic anemia (AA). The patient was refractory to 10-months of immunosuppressive therapy with cyclosporine, prednisone, and antithymocyte globulin. She was eventually treated with allogeneic stem cell transplantation (allo-SCT). On Day +323 the patient continues to be transfusion-independent. This case illustrates how in patients with thymoma and AAMT may herald development of AA. This is also the first report of a patient with AAMT progressing to thymoma-associated AA being successfully treated with allo-SCT. ...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Coagulopathic side effect of L-asparaginase on fibrinogen level in childhood acute lymphoblastic leukemia during induction phase
Publication date: Available online 1 February 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Alauldeen Mudhafar Zubair Alqasim, Raji Hussein Al-Hadithi, Aseel Nashaat Al-KhalidiAbstractBackgroundL-asparaginase is chemotherapeutic agent commonly used in treatment of Acute Lymphoblastic Leukemia. Thromboembolic and to a lesser extent bleeding events are serious complications associated with administration of this drug during the induction phase in ALL especially in children resulting from reduced synthesis of proteins such as Antithrombin & fibrinogen.ObjectiveEvaluation of the coagulopathic side effect ...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease
ConclusionPatients with steroid-refractory GI aGVHD had higher fecal calprotectin levels and lower albumin levels than patients with steroid-responsive disease. We recommend further studies to evaluate non-invasive tests with fecal calprotectin in combination with albumin in predicting steroid refractory disease at onset of symptoms to potentially identify patients that may benefit from upfront escalation in GVHD treatment. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA)
Publication date: Available online 1 February 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Sarbajit Mukherjee, Adanma Ayanambakkam, Sami Ibrahimi, Sarah Schmidt, Jennifer Holter Charkrabarty, Mohamad KhawandanahAbstractIbritumomab Tiuxetan (Zevalin) is an anti CD-20 murine monoclonal antibody linked to the radio-isotope 90-yttrium (90Y) by the chelator Tiuxetan. It is FDA approved for treatment of relapsed low grade or follicular B-cell Non-Hodgkin's Lymphoma (NHL) or newly diagnosed follicular NHL following an initial response to first-line chemotherapy. Patients may develop Human Anti-Murine Antibodies...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Skin involvement in Burkitt’s lymphoma
We report a case of a 9-years old boy with stage 4 Burkitt's lymphoma with skin involvement who tested negative for human immune-deficiency virus. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Beliefs about hydroxyurea in youth with sickle cell disease
Publication date: Available online 2 February 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Sherif M. Badawy, Alexis A. Thompson, Robert I. LiemAbstractBackgroundHydroxyurea reduces complications and improves health-related quality of life (HRQOL) in sickle cell disease (SCD) patients, however adherence remains suboptimal. Understanding patients’ views of hydroxyurea is critical to optimize adherence, particularly in adolescents and young adults (AYA). Study objectives were to assess beliefs about hydroxyurea using the Beliefs about Medicines Questionnaire (BMQ), and to examine the relationship of p...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Damocles’ syndrome revisited: Update on the fear of cancer recurrence in the complex world of today’s treatments and survivorship
ConclusionLiterature on the fear of cancer recurrence has begun to emerge. However, herein we provide a unique approach through the use of a metaphor: Cicero’s story of Damocles’ sword. We aim to outline the many fear-related and emotional challenges faced by cancer survivors with an extensive review of studies demonstrating such challenges. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning
Publication date: Available online 20 February 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Can Boga, Mahmut Yeral, Ciğdem Gereklioglu, Suheyl Asma, Erkan Maytalman, Pelin Aytan, Ilknur Kozanoglu, Cagla Sariturk, Hakan OzdoguAbstractObjective/backgroundAnti-T lymphocyte globulin Fresenius (rATG-F; ATG-Fresenius) and antithymocyte globulin (thymoglobulin), which are included in transplant protocols, are used to reduce the risk of chronic graft-versus-host disease (cGVHD) or suppress allograft rejection. Available clinical studies have been conducted in heterogenous patient populations and with different ...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience
ConclusionR–MTX–ARA-C followed by autologous stem cell transplantation seems a promising strategy with high response rates in PCNSL. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

End of therapy minimal residual disease (MRD) measurement in children with ALL does not predict relapse
Publication date: March 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 1Author(s): Tahani Hani Sarrawi, Ismael Zayyat, Fareed Barakat, Maha Rezeq, Salam Abu Jmaian, Faris MadanatAbstractMinimal residual disease (MRD) monitoring opened a new era for childhood acute lymphoblastic leukemia (ALL), and is widely used for risk adapted therapy in the major study groups (Borowitz et al. 2015; Eckert et al., 2015; Peregud-Pogorzelsk et al., 2003). MRD is measured either by polymerase chain reaction (PCR) or flow cytometry (FCM) (Campana, 2009). Most studies have concentrated on measuring MRD during or at en...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Polycythemia vera masked due to severe iron deficiency anemia
We present a case where there was a delay in the diagnosis of polycythemia because of menorrhagia in the past. On admission, the patient presented with elevated red and white blood cell counts, erythropoietin was low, and polycythemia was then suspected. A bcr-abl test was performed to rule out chronic myelogenous leukemia. JAK2 mutation was positive, and the patient was diagnosed with polycythemia vera. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Severe Plasmodium vivax cerebral malaria complicated by hemophagocytic lymphohistiocytosis treated with artesunate and doxycycline
Publication date: March 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 1Author(s): Sawsan Amireh, Hamid Shaaban, Gunwant GuronAbstractMalaria-related hemophagocytic lymphohistiocytosis is a rare, potentially fatal, hyperinflammatory disease entity which can be challenging to diagnose and treat. It is usually associated with Plasmodium falciparum infection. It is less frequently associated with Plasmodium vivax. Here we report an unusual case of a 23-year-old healthy Nigerian man who presented with fever, microangiopathic hemolytic anemia, acute renal failure, and confusion, and was diagnosed as hav...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer
ConclusionThe combination of neoadjuvant chemotherapy with wP + wCb before anthracycline chemotherapy can be tolerated by patients with triple-negative breast cancer. Complete pathologic response rates were comparable with those historically seen. Careful selection of patients is fundamental as this regimen is associated with a high incidence of hematologic toxicity. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Impact of vitamin D deficiency on increased blood eosinophil counts
Publication date: March 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 1Author(s): João Tadeu Damian Souto Filho, Alícia Souza de Andrade, Felipe Mesquita Ribeiro, Paola de Araujo Sardenberg Alves, Virgínia Ribeiro Fernandes SimoniniAbstractObjective/backgroundVitamin D has been increasingly recognized as an immunomodulatory agent. Its deficiency has been associated with immune-mediated diseases such as asthma, rhinitis, and atopic dermatitis. These allergic conditions are dependent on T-helper type 2 (Th2) cells secreting interleukins, overproduction of immunoglobulin E (IgE),...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies
Publication date: March 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 1Author(s): Hind Rafei, Mohamed A. Kharfan-DabajaAbstractMore effective therapies are emerging, with better toxicity profiles, and are being incorporated into modern treatment algorithms of chronic lymphocytic leukemia at various stages of the disease, including for patients harboring Del17p and/or aberrant TP53. Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, has demonstrated impressive response rates in the relapsed/refractory setting, including in the setting of Del17p and/or TP53 mutations. Venetoclax, an inhibito...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Hematological parameters and red blood cell morphological abnormality of Glucose-6-Phosphate dehydrogenase deficiency co-inherited with thalassemia
ConclusionG-6-PD deficiency co-inherited with thalassemia in males was present in 10% of the participants, resulting in worsening of red blood cell pathology compared with inheritance of thalassemia alone. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation
ConclusionLow fixed dose defibrotide initiated early seems to be effective and safe in treatment of VOD. This is relevant in a resource limited setting and warrants prospective evaluation. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation
Publication date: March 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 1Author(s): Rosario Varela Gómez, Goretti Vázquez Vázquez, Victor Noriega Concepción, Andrea Galego García, Concepción Andón SaavedraAbstractThe literature reports an incidence of Pure Red Cell Aplasia (PRCA) ranging from 6-30% of all cases of ABO-incompatible HSCT. Although most patients resolve spontaneously after withdrawal immunosuppression, some of them require more aggressive treatment to manage this condition. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?
Publication date: Available online 16 March 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Erden Atilla, Ugur Sahin, Pinar Ataca Atilla, Mustafa Merter, Elif Ozyurek, Koray Ceyhan, Sinem Civriz BozdagAbstractPrimary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has been widely used for treatment of relapsed/refractory NHL patients. However there are limited data whethe...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

The relation between protein Z polymorphism and the risk of thrombosis in Egyptian patients with antiphospholipid syndrome
Publication date: Available online 17 April 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Yomna K. Eissa, Hend N. Ellithy, Sherif M. Yousry, Zakaria IsmailAbstractBackgroundThe genetic background plays an important role in thrombosis and pregnancy morbidities. Low levels of protein Z is associated with increased risk of thrombosis. The G79A polymorphism in the protein Z gene may be a genetic risk factor for thrombosis.Aim of the studyTo investigate the prevalence and clinical significance of the protein Z-79 G/A gene polymorphism in Egyptian patients with antiphospholipid syndrome (APS).MethodsWe genotype...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Predictors of outcome in patients with hematologic malignancies admitted to the intensive care unit
ConclusionOverall hospital outcome of critically ill patients with HM is improving. However those who require mechanical ventilation or underwent allogeneic HSCT continue to have poor outcome. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Myeloid sarcoma with megakaryoblastic differentiation presenting as a breast mass
We report a case of myeloid sarcoma with megakaryoblastic differentiation in the breast of a patient with history of essential thrombocythemia. The mass was composed of undifferentiated pleomorphic malignant cells in trabecular cords and nests with many scattered giant malignant cells and brisk abnormal mitoses. On immunohistochemistry, the neoplastic cells were positive for CD61, CD31, CD34, Factor VIII and CD43 which confirmed the diagnosis. To our knowledge, this is the first report of myeloid sarcoma with megakaryoblastic morphology occurring in the breast. Here we discuss the clinicopathologic features of this rare en...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma
We describe the case of a young patient with metastatic hepatocellular cancer who developed rapid and fatal tumor lysis syndrome following initiation of sorafenib therapy. Although rare with sorafenib therapy for hepatocellular carcinoma, tumor lysis syndrome is serious complication. Patients with a high burden of disease at therapy initiation should have their metabolic parameters measured prior to starting therapy and closely followed for the first 1–2 weeks while being treated. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma
We present a comparison of mobilisation outcomes using these regimens.Patients and methodsVino-Cy patients received Vinorelbine 25 mg/m2 on day 1, cyclophosphamide 1500 mg/m2 on day 2, and pegylated GCSF on day 4 or GCSF 10 mcg/kg/day from day 4 onwards. Cy patients were given cyclophosphamide 4000 mg/m2 on day 1 and GCSF10 mcg/kg/day from day 5 onwards. The target CD34 + SC collection was 5 × 106 per kg/BW.Results149 patients were included. SC collection was lower in the Vino-Cy group (8.20 × 106/Kg BW) compared to the Cy group (11.43 × 106/Kg BW), with adjusted geometric mean...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Intravenous compared to oral busulfan with cyclophosphamide for autologous hematopoietic cell transplant conditioning for plasma cell myeloma
Publication date: Available online 24 April 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Moaath Mustafa Ali, Donna M. Corrigan, Lisa A. Rybicki, Melissa A. Yurch, Kelly Cherni, Hien Liu, Robert Dean, Betty Hamilton, Brad Pohlman, Steven Andresen, Matt Kalaycio, Brian J. Bolwell, Navneet S. Majhail, Ronald Sobecks (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Diagnostic utility of glycosyltransferase mRNA expression in gastric cancer
ConclusionThis study revealed the potential of ppGalNAc-T6 and ST6GalNAc-I mRNA transcript levels in serum as markers of gastric cancer. Further studies on the wider range of glycosyltransferases in various cancers are needed to establish signature mRNA batteries as minimally invasive markers of gastric cancer. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer
Publication date: Available online 19 May 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Hikmat Abdel-RazeqAbstractDespite the recent advances in breast cancer early detection and awareness, a significant portion of patients present with an advanced-stage disease and more patients will progress to stage IV despite adequate treatment of their initial early-stage disease. Hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor-2 (HER2)-negative subtype is the commonest among all breast cancer subtypes. The management of the advanced-stage disease of this subtype has evolved significantly over ...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Bizarre multilobated myeloma cells mimicking megakaryocytes
Publication date: Available online 19 May 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Sunil Pasricha, Neha Singh, Ajit Panaych, Anurag Mehta (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Limited role of bone marrow biopsy for detection of marrow involvement in patients with Hodgkin lymphoma from the Middle East and North Africa region
Publication date: June 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 2Author(s): Moussab Damlaj, Gamal Gmati, Ghulam Syed, Tabrez Pasha, Hend Salama, Osama Ali, Khadega A. Abuelgasim, Mohsen Al-Zahrani, Ahmad Al Askar, Ayman Alhejazi (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations
ConclusionDNMT3A R882 mutation plays an important role in CN-AML patients’ prognosis and clinical outcomes in the presence and absence of NPM1 and FLT3 mutations. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort
We examined the adoption of the new comorbidity index (HCT-CI/Age) proposed by the Seattle group after the addition of age variable and compared it to the pre-transplant assessment of mortality (PAM) that already incorporates age as part of its evaluation criteria.MethodsA retrospective analysis of adult patients who underwent HCT at our institution from January 2010 through August 2014 was performed. Kaplan-Meier’s curve, log-rank tests, Cox model and Pearson correlation was used in the analysis.ResultsOf the 114 patients that underwent allogeneic transplant in our institution, 75.4% were ≥40 years old. More th...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient
Publication date: June 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 2Author(s): Ernesto Ayala, Denise LaFave, Taiga Nishihori, Mohamed A. Kharfan-DabajaAbstractHemophagocytic lymphohistiocytosis (HLH) is a rare but severe and often overwhelming systemic hyper-inflammatory syndrome generally presenting with unexplained fevers, hepatosplenomegaly, and progressive multi-organ dysfunction. Treatment of HLH has two major goals: Halting the triggering event and controlling the overactive immune system. However, patients with primary or recurrent secondary HLH should subsequently undergo allogeneic HCT ...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Acute promyelocytic leukemia with increased bone marrow reticulin fibrosis: Description of three cases and review of the literature
Publication date: June 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 2Author(s): Iman Abou Dalle, Samer Nassif, Ali BazarbachiAbstractPathologic increase in bone marrow reticulin fibrosis can be present in many malignant hematopoietic diseases. In acute leukemia, one-third of patients have some degree of marrow reticulin fibrosis at presentation, which is thought to be related to cytokine release from blasts. Marrow fibrosis is particularly common in acute megakaryoblastic leukemia, while this change is rarely seen in acute promyelocytic leukemia. Six case reports of acute promyelocytic leukemia w...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research